Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To follow up, https://rarediseases.oscar.ncsu.edu/disease/rabies/research/
IMT504 is the oldest FDA preaproved drug to go to clinical. It can clearly get funded by a government or someone rich if there is a push.
If you look at the FDA's site, this (IMT504) is the first drug approved (theres about 3 in the pipeline, IMT504 being the oldest) to go to clinical trial for a rabies vaccine booster. If some rich person in the countryside who has to deal with rabies from animal hunting or something has his son die to a bite, yeah I could see that.
friend and i guessed its the new accountant
Philanthropy or grants, remember these are orphan diseases and most clinical trials for orphan diseases are funded by grants.
If they're more than 5% stakeholders we will find out next report
???? I expected this because they created series C preferred, but it doesnt mean it didnt happen. In the latest disclosure...
(a) Stockholders equity (deficit) In November 2020, the Company amended its Articles of Incorporation with the
following three actions: 1 - changed the par value of the common stock from $0.001 to $0.0001; 2 - increased the Series
A preferred stock authorised to 134,109,750 shares from 34,109,750; and 3 - established and authorized 30,000,000 shares
Series C preferred stock.
The rights and privileges of Series A and Series B remain unchanged. The rights and privileges of Series C are:
Series C carry 1 vote for each share of as converted common stock; is convertible into common stock aggregating 30%,
post conversion, of the total issued and outstanding common shares at conversion date
In November 2020, the Company issued 100,000,000 shares of Series A preferred stock in exchange for services valued
at $0.0001 per share or $10,000 in total.
In November 2020, the Company issued 30,000,000 shares of Series C preferred stock in exchange for services valued at
$0.0001 per share or $3,000 in total. These shares vest 50% at November 30, 2020 and the remaining 50% at May 31, 2021.
sad to see dilution but at least its holding its price
They got an accountant
3 Drug deals no?
They did, but the investor tab has been reworked to include the coming soon stuff, pretty hyped to see their investor calendar.
https://www.federalregister.gov/documents/2020/10/22/2020-23386/prospective-grant-of-an-exclusive-patent-license-development-of-a-direct-ocular-administered
are we going to see a PR about this tomorrow? hold on boys
4m volume, but down, what gives?
I really like the person who bought just 2 shares
Sad we didnt finish above .04, at least the VWAP was above .04, and this stock is going places.
It would only uplist after ya know, a clinical trial, meaning it would have a valuable tangible asset.
Almost like people bought last friday and monday at 80 and 10 mil vol, vs today that wont even have 3.
Thanks, didn't know about the waiver, so dilution *may* not be an issue depending on the road they go down.
https://www.federalregister.gov/documents/2017/09/28/2017-20799/fee-for-using-a-tropical-disease-priority-review-voucher-in-fiscal-year-2018
PRV application is around 3 million (basically my low ball of what they need), unless I'm misreading something. And we dont know if they're going down a grant exclusive route or not yet.
Considering the trial isn't until early 2022, I will end up making a DD explaining IMT504 and will prolly explain why I think it'll work or not before the trial, sometime early next year or later this year.
I've been reading more about the rat trials with IMT504, I'm definitely holding until at least the middle of the phase 1 trial, and will decide based on trial sponsors where to go from there. This drug in every study says it's extremely safe, so I expect the trial to finish, though I'm currently unconvinced atm whether it'll be a positive or negative result (need to do more analysis of the rat trials and preclincal human trials, as there is a lot of papers to read), but what I am positive in is Paul to negotiate the deals to get it to a well deserving trial.
This will accumulate to 30 cents to a dollar by end of Q1 next year (prolly sooner), and will flux between that until the trial starts (unless its a high quality trial from a well recognized hospital or university, then it might be over a dollar).
One thing I am worried about is the restructuring of the stock to add class B+C preferred stock, which indicates to me that there will be dilution of preferred stock (not float thankfully), which could harm the price, but considering the smaller ss atm, it should be able to handle it, considering they will only need to raise 10-30 mil in funds (prv application + running trials).
Is it though? Like that's median over phase 1, phase 2, and phase 3 trials, with a bias towards phase 1 and phase 2 trials. Considering phase 3 trials on average only cost 19 million, that's not too out of reach considering yeah, less regulation means cheaper so I doubt this would be on the upper end of that number, though we will have to see what numbers they put out.
There ya go, now you're reading why this market space is so potentially explosive.
They fund trials too, not just research, as trials are part of the research process. And yes unregulated in this case is sort've the wrong word, less regulated is more accurate as orphan drug designations usually mean lower standards and faster approval times from the FDA, as some of the testing requirements are lower (hard to be specific without know what they're aiming for, as I assume they will put this out before the phase 1 trial begins).
https://ojrd.biomedcentral.com/articles/10.1186/s13023-020-01514-5
It's not that hard to google. There's a reason this sector is unregulated and has a lot of money thrown via grants. This is prolly the primary reason a pink sheets company even got the license to begin with, no one wants to do it. Paul should be able to negotiate with a university to conduct the trials + the university to get a grant from the NIH or FDA.
I personally expect this to accumulate to the price of the drug plus the price of the PRV as news gets announced about stuff like university partnerships to do the clinical trials, along with other details (so around 1 dollar). If the trials are ran successfully, this shows the company knew it was doing and it will stabilize around the price, maybe dip. If the trials are run successfully and there is a positive result, 4-5x the value at least, perhaps more, considering they have an agreement to sell a cure to rabies, without FDA regulation or have a childhood brain cancer therapeutic that can be sold for tons of money (so around 5-10 dollars a share). Keep in mind this is at least 24 months out. This company has seemingly always been ahead of schedule, and Paul being experienced probably already has trial locations + dates in mind that he has through negotiate to with funders.
What's the odds of all this happening? Perfectly? 0. But at this price point its definitely worth the risk imo considering he has made these deals for a 100 billion dollar company.
My driver's license isn't exclusive for me to be the only person to drive a car.
What do you even mean no terms disclosed? Look on the nih's site about what a technology transfer is. https://www.ott.nih.gov/licensing there are your terms.
It's late on a friday, people have already gone home... this dump is less than 2 million shares on a company that just had a 72 m share day, and about 50m of that above .045... run on monday
I think this stock is very different because, what will it take for it to go down? Failed clinical trial in 18 months? Not being able to find a university to conduct the two trials? Remember Paul worked as a negotiator/exec at a multi-billion dollar company. I highly doubt he will fail to secure at least a trial itself. Whether or not the drugs work... well we will find out in 12-18 months, but we will def get more runs when they announce the trial, announce funding, announce university partnerships etc.
We all knew this was coming, slightly priced in already.
What about the deal that's supposed to close within a week or so? Are they not going to announce it closing?
52 week low for this company is a bit disingenuous because it is a former shell that was tabled and bought out. Yes technically it got into triple 0's before the buy out, but ever since then .006 was the low iirc?
Sure, that's why replied to his post and not yours, I do think the underlying company is good enough for the risk for your reasons given, which is why I'm here.
I don't think it isn't happening, I said in my post explicitly it is happening, I'm saying that using that as a heuristic is dumb and worse than gambling because you not only don't get the profit they do, they already price in the change so it's a bad buy for you. MM's typically have actuarial sheets to make their buys anyways, with or without insider information, and that information clearly isn't the same for you or me.
It's a lie people tell themselves to make their buys feel better, only buy and believe based on news and expectation of news. Anything else is exactly as you said, illegal (though it wouldn't be the first time a penny stock has done something illegal) or straight up bad gambling.
no not at all, but I hope it will
Getting this from the government tends to drive stocks up like crazy, if they get the cancer treatment and start licensing it, it could def go way north of .05
Also, there's this PR that was never followed up on https://connectyx.com/press-releases/july-06-2020/
not sure if the deal fell through or its taking longer cuz of corona.
There's also the NIH patent they applied for exclusivity for that we can hear back from any day though (since 15 days was up about a week ago).